Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.
Journal of Immunological Methods|April 3, 2017
Lot-to-lot stability of antibody reagents for flow cytometrySebastian Böttcher, Vincent H J van der Velden, Neus Villamor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trialSebastian Böttcher, Matthias Ritgen, Kirsten Fischer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2010
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromesNicolaus Kröger, Ulrike Bacher, Peter Bader, et al.
Cancers|March 25, 2022
Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO)Sabrina Jotschke, Susann Schulze, Nadja Jaekel, et al.
JMIR Research Protocols|December 16, 2020
Remote Assessment of Disease and Relapse in Epilepsy: Protocol for a Multicenter Prospective Cohort StudyElisa Bruno, Andrea Biondi, Sebastian Böttcher, et al.
Blood|February 26, 2013
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trialPeter Dreger, Andrea Schnaiter, Thorsten Zenz, et al.
Journal of Immunological Methods|August 28, 2019
EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsetsJuan Flores-Montero, Georgiana Grigore, Rafael Fluxá, et al.
Leukemia|December 21, 2018
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemiaJulia von Tresckow, Paula Cramer, Jasmin Bahlo, et al.
Oncotarget|November 12, 2015
Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonalityPaloma Bárcena, María Jara-Acevedo, María Dolores Tabernero, et al.
Pageof 9